New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations
Pulmonary arterial hypertension (PAH) is one of the most severe cardiovascular disorders. It is characterised by progressing clinical course, right ventricular failure development, and very poor prognosis. In September 2009, the European Society of Cardiology and the European Respiratory Society rel...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2048 |
| _version_ | 1797882621420634112 |
|---|---|
| author | T. V. Martynyuk S. N. Nakonechnikov I. E. Chazova |
| author_facet | T. V. Martynyuk S. N. Nakonechnikov I. E. Chazova |
| author_sort | T. V. Martynyuk |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is one of the most severe cardiovascular disorders. It is characterised by progressing clinical course, right ventricular failure development, and very poor prognosis. In September 2009, the European Society of Cardiology and the European Respiratory Society released a new revision of clinical recommendations on pulmonary hypertension (PH) diagnostics and treatment. The recommendations review the evidence for supportive therapy (oral anticoagulants, diuretics, digitalis medications, and oxygen), specific therapy (calcium antagonists, prostanoids, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors), and surgery. Modern pharmaceutical approaches, including specific therapy medications and their combinations, could increase the effectiveness of PH treatment and improve PH prognosis. The meta-analysis of 23 randomised trials demonstrated that in PAH patients, specific therapy (mean duration 14,3 weeks) decreased mortality and hospitalisation rates by 43% and 61%, respectively. In other countries, specific therapy medications are included into targeted treatment programs. In Russia, only bosentan is officially recommended for PAH treatment, while the registration of inhaled iloprost and sildenafil citrate is expected in the nearest future. |
| first_indexed | 2024-04-10T03:38:46Z |
| format | Article |
| id | doaj.art-ca09341a332c47f6a4d28179104b6071 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:38:46Z |
| publishDate | 2010-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-ca09341a332c47f6a4d28179104b60712023-03-13T07:23:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-04-019286991760New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendationsT. V. Martynyuk0S. N. Nakonechnikov1I. E. Chazova2Институт клинической кардиологии им. А.Л.Мясникова ФГУ “Российский кардиологический научно-производственный комплекс Росмедтехнологии”. МоскваИнститут клинической кардиологии им. А.Л.Мясникова ФГУ “Российский кардиологический научно-производственный комплекс Росмедтехнологии”. МоскваИнститут клинической кардиологии им. А.Л.Мясникова ФГУ “Российский кардиологический научно-производственный комплекс Росмедтехнологии”. МоскваPulmonary arterial hypertension (PAH) is one of the most severe cardiovascular disorders. It is characterised by progressing clinical course, right ventricular failure development, and very poor prognosis. In September 2009, the European Society of Cardiology and the European Respiratory Society released a new revision of clinical recommendations on pulmonary hypertension (PH) diagnostics and treatment. The recommendations review the evidence for supportive therapy (oral anticoagulants, diuretics, digitalis medications, and oxygen), specific therapy (calcium antagonists, prostanoids, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors), and surgery. Modern pharmaceutical approaches, including specific therapy medications and their combinations, could increase the effectiveness of PH treatment and improve PH prognosis. The meta-analysis of 23 randomised trials demonstrated that in PAH patients, specific therapy (mean duration 14,3 weeks) decreased mortality and hospitalisation rates by 43% and 61%, respectively. In other countries, specific therapy medications are included into targeted treatment programs. In Russia, only bosentan is officially recommended for PAH treatment, while the registration of inhaled iloprost and sildenafil citrate is expected in the nearest future.https://cardiovascular.elpub.ru/jour/article/view/2048легочная артериальная гипертензияантагонисты кальцияантикоагулянтыдиуретикиантагонисты рецепторов эндотелинапростаноидыингибиторы фосфодиэстеразы типа 5 |
| spellingShingle | T. V. Martynyuk S. N. Nakonechnikov I. E. Chazova New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations Кардиоваскулярная терапия и профилактика легочная артериальная гипертензия антагонисты кальция антикоагулянты диуретики антагонисты рецепторов эндотелина простаноиды ингибиторы фосфодиэстеразы типа 5 |
| title | New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations |
| title_full | New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations |
| title_fullStr | New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations |
| title_full_unstemmed | New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations |
| title_short | New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations |
| title_sort | new perspectives in pulmonary arterial hypertension treatment 2009 european recommendations |
| topic | легочная артериальная гипертензия антагонисты кальция антикоагулянты диуретики антагонисты рецепторов эндотелина простаноиды ингибиторы фосфодиэстеразы типа 5 |
| url | https://cardiovascular.elpub.ru/jour/article/view/2048 |
| work_keys_str_mv | AT tvmartynyuk newperspectivesinpulmonaryarterialhypertensiontreatment2009europeanrecommendations AT snnakonechnikov newperspectivesinpulmonaryarterialhypertensiontreatment2009europeanrecommendations AT iechazova newperspectivesinpulmonaryarterialhypertensiontreatment2009europeanrecommendations |